SCHEMBL487841

SCHEMBL487841

Cc1ccc(Cl)c(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561566 1.00
SCHEMBL876343 0.78
SCHEMBL266594 0.78
SCHEMBL30019312 0.78
SCHEMBL4022308 0.74
SCHEMBL7662004 0.74
SCHEMBL16046525 0.74
SCHEMBL21856101 0.74
SCHEMBL18149177 0.74
SCHEMBL7484181 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
EP-3898646-B1 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF SAGE THERAPEUTICS LLC (US) 2026-02-18 EP disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 US disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 US disclosed
EP-4161927-B9 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-11-06 EP disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20070043011-A1 Substituted benzanilide compound and noxious organism controlling agent MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-02-22 US disclosed
US-20070043011-A1 Substituted benzanilide compound and noxious organism controlling agent MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-02-22 US disclosed
US-20060052366-A1 Pyridine derivatives as fungicidal compounds BAYER SAS (FR) 2006-03-09 US disclosed
EP-1597252-A1 PYRIDINE DERIVATIVES AS FUNGICIDAL COMPOUNDS Bayer CropScience S.A. (FR) 2005-11-23 EP disclosed
WO-2004074280-A1 PYRIDINE DERIVATIVES AS FUNGICIDAL COMPOUNDS BAYER CROPSCIENCE SA (FR) 2004-09-02 WO disclosed
EP-1449841-A1 New fungicidal compounds Bayer CropScience SA (FR) 2004-08-25 EP disclosed
WO-2000039088-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-07-06 WO disclosed
US-4898608-A Pyridylthio-acylanilide herbicides BAYER AKTIENGESELLSCHAFT (DE) 1990-02-06 US disclosed
EP-0243868-A2 Pyridylthio-acylanilides BAYER AG (DE) 1987-11-04 EP disclosed
US-4594422-A Hydroxylation of a 6-halo picolinic acid with a aqueous mineral acid solution; then halogenating THE DOW CHEMICAL COMPANY (US) 1986-06-10 US disclosed